Business Of Biotech

Running Interference: RNAi with Silence Therapeutics' Craig Tooman

Matt Pillar

We love to hear from our listeners. Send us a message.

Fresh on the heels of his appointment as President & CEO at Silence Therapeutics, Craig Tooman joins the Business of Biotech to share how he applies his finance-minded leadership to steward the advance of the company's deepening pipeline of gene silencing candidates.  Tooman also shares insight into the IP and the people responsible for managing that deep pipeline, which spans indications from hematology to cardiovascular disease to rare diseases. 

Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.

Subscribe to our monthly Business of Biotech newsletter.

Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.com

Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/


People on this episode

Podcasts we love

Check out these other fine podcasts recommended by us, not an algorithm.